GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Cyclically Adjusted Price-to-FCF

SILO Pharma (SILO Pharma) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


SILO Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for SILO Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma Cyclically Adjusted Price-to-FCF Chart

SILO Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SILO Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SILO Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, SILO Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Cyclically Adjusted Price-to-FCF falls into.



SILO Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

SILO Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, SILO Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.292/131.7762*131.7762
=-0.292

Current CPI (Mar. 2024) = 131.7762.

SILO Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.381 100.560 -0.499
201409 -0.053 100.428 -0.070
201412 -0.236 99.070 -0.314
201503 -0.470 99.621 -0.622
201506 -0.225 100.684 -0.294
201509 -0.254 100.392 -0.333
201512 -0.055 99.792 -0.073
201603 -0.188 100.470 -0.247
201606 -0.106 101.688 -0.137
201609 0.116 101.861 0.150
201612 0.036 101.863 0.047
201703 -0.084 102.862 -0.108
201706 -0.129 103.349 -0.164
201709 -0.064 104.136 -0.081
201712 -0.007 104.011 -0.009
201803 0.184 105.290 0.230
201806 0.289 106.317 0.358
201809 -0.050 106.507 -0.062
201812 -0.172 105.998 -0.214
201903 -0.321 107.251 -0.394
201906 -0.324 108.070 -0.395
201909 -0.426 108.329 -0.518
201912 -0.622 108.420 -0.756
202003 -0.250 108.902 -0.303
202006 -0.316 108.767 -0.383
202009 -0.166 109.815 -0.199
202012 -0.314 109.897 -0.377
202103 -0.187 111.754 -0.221
202106 -0.269 114.631 -0.309
202109 -0.332 115.734 -0.378
202112 -0.388 117.630 -0.435
202203 -0.400 121.301 -0.435
202206 -0.201 125.017 -0.212
202209 -0.711 125.227 -0.748
202212 -0.279 125.222 -0.294
202303 -0.219 127.348 -0.227
202306 -0.174 128.729 -0.178
202309 -0.345 129.860 -0.350
202312 -0.314 129.419 -0.320
202403 -0.292 131.776 -0.292

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SILO Pharma  (NAS:SILO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


SILO Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma (SILO Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632
SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797